Literature DB >> 12709915

Hemostasis during normal pregnancy and puerperium.

Margareta Hellgren1.   

Abstract

During normal pregnancy the hemostatic balance changes in the direction of hypercoagulability, thus decreasing bleeding complications in connection with delivery. The most important initial factor for acute hemostasis at delivery is, however, uterine muscle contractions, which interrupt blood flow. Global tests such as Sonoclot signature, the Thromboelastogram, and a new method analyzing overall plasma hemostasis, all show changes representative of hypercoagulability during pregnancy. Increased endogenous thrombin generation, acquired activated protein C resistance, slightly decreased activated partial thromboplastin time (aPTT) and increased prothrombin complex level (PT) measured as international normalized ratio (INR) of less than 0.9 have been reported as well. In normal pregnancy, the platelet count is within normal range except during the third trimester when benign gestational thrombocytopenia, 80 to 150 x 10 9/L, can be observed. Platelet turnover is usually normal. Activation of platelets and release of beta-thromboglobulin and platelet factor 4 are reported. The bleeding time is unchanged during normal pregnancy. Most blood coagulation factors and fibrinogen increase during pregnancy. Factor (F) XI is the only blood coagulation factor that decreases. Blood coagulation inhibitors are mainly unchanged but the level of free protein S decreases markedly and the level of tissue factor pathway inhibitor increases. Thrombomodulin levels increase during pregnancy. Fibrinolytic capacity is diminished during pregnancy, mainly because of markedly increased levels of plasminogen activator inhibitor-1 (PAI-1) from endothelial cells and plasminogen activator inhibitor-2 (PAI-2) from the placenta. Thrombin-activated fibrinolysis inhibitor is reported to be unaffected. The total hemostatic balance has been studied by analyses of prothrombin fragment 1+2, thrombin-antithrombin complex, fibrinopeptide A, soluble fibrin, D-dimer, and plasmin-antiplasmin complex. There is activation of blood coagulation and a simultaneous increase in fibrinolysis without signs of organ dysfunction during normal pregnancy. These changes increase as pregnancy progresses. During delivery, there is consumption of platelets and blood coagulation factors, including fibrinogen. Fibrinolysis improves and increases fast following childbirth and expulsion of the placenta, resulting in increased D-dimer levels. These changes are self-limiting at normal delivery. The hemostatic changes, noted during pregnancy, normalize after delivery within 4 to 6 weeks. Platelet count and free protein S, however, can be abnormal longer. Hemostasis should not be tested earlier than 3 months following delivery and after terminating lactation to rule out influences of pregnancy. PAI-1 and PAI-2 levels decrease fast postpartum, but PAI 2 has been detected up to 8 weeks postpartum. alpha 2 -antiplasmin, urokinase, and kallikrein inhibitor levels have been reported to be increased 6 weeks postpartum.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12709915     DOI: 10.1055/s-2003-38897

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  65 in total

Review 1.  Nonclinical aspects of venous thrombosis in pregnancy.

Authors:  Evi Struble; Wafa Harrouk; Albert DeFelice; Belay Tesfamariam
Journal:  Birth Defects Res C Embryo Today       Date:  2015-09-25

2.  The cost-benefit ratio of screening pregnant women for thrombophilia.

Authors:  Gian Luca Salvagno; Giuseppe Lippi; Massimo Franchini; Giovanni Targher; Martina Montagnana; Massimo Franchi; Gian Cesare Guidi
Journal:  Blood Transfus       Date:  2007-11       Impact factor: 3.443

3.  Thrombelastography Should Be Included in the Algorithm for the Management of Postpartum Hemorrhage.

Authors:  Csilla Jámbor; Sybille A Kozek-Langenecker; Thomas Frietsch; Ralf Knels
Journal:  Transfus Med Hemother       Date:  2008-09-16       Impact factor: 3.747

Review 4.  Postoperative adhesion development following cesarean and open intra-abdominal gynecological operations: a review.

Authors:  Awoniyi O Awonuga; Nicole M Fletcher; Ghassan M Saed; Michael P Diamond
Journal:  Reprod Sci       Date:  2011-07-20       Impact factor: 3.060

Review 5.  The adaptation of the cerebral circulation to pregnancy: mechanisms and consequences.

Authors:  Marilyn J Cipolla
Journal:  J Cereb Blood Flow Metab       Date:  2013-01-16       Impact factor: 6.200

6.  The Equine PeptideAtlas: a resource for developing proteomics-based veterinary research.

Authors:  Louise Bundgaard; Stine Jacobsen; Mette A Sørensen; Zhi Sun; Eric W Deutsch; Robert L Moritz; Emøke Bendixen
Journal:  Proteomics       Date:  2014-02-16       Impact factor: 3.984

7.  Premature labor: a state of platelet activation?

Authors:  Offer Erez; Roberto Romero; Debra Hoppensteadt; Jawed Fareed; Tinnakorn Chaiworapongsa; Juan Pedro Kusanovic; Shali Mazaki-Tovi; Francesca Gotsch; Nandor Gabor Than; Edi Vaisbuch; Chong Jai Kim; Jimmy Espinoza; Pooja Mittal; Neil Hamill; Chia-Ling Nhan-Chang; Moshe Mazor; Sonia Hassan
Journal:  J Perinat Med       Date:  2008       Impact factor: 1.901

8.  Uneventful cesarean delivery with administration of factor XI concentrate in a patient with severe factor XI deficiency.

Authors:  Georgios Mavromatidis; Konstantinos Dinas; Dimitrios Delkos; Fotios Goutzioulis; Christos Vosnakis; Emmanouel Hatzipantelis; Vassilia Garipidou; David Rousso
Journal:  Int J Hematol       Date:  2007-10       Impact factor: 2.490

Review 9.  Combined use of rapid D-dimer testing and estimation of clinical probability in the diagnosis of deep vein thrombosis: systematic review.

Authors:  Tonya L Fancher; Richard H White; Richard L Kravitz
Journal:  BMJ       Date:  2004-09-21

10.  Tissue factor-dependent thrombin generation across pregnancy.

Authors:  Kelley C McLean; Ira M Bernstein; Kathleen E Brummel-Ziedins
Journal:  Am J Obstet Gynecol       Date:  2012-06-11       Impact factor: 8.661

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.